Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A next-generation sequencing–based assay for minimal residual disease assessment in AML patients with FLT3-ITD mutations

11 Apr 2018

Abstract excerpt

Key Points A sensitive and specific assay was developed for detection of MRD in patients with AML who harbor FLT3-ITD mutations. This standardized assay is readily available and may be used to guide therapy decisions in patients with AML.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acute Myeloid Leukemia Research
Share to Protein Degradation and Inhibitors
Share to Vascular Tumors and Angiosarcomas

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 29643105
DOI: 10.1182/bloodadvances.2018015925

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A next-generation sequencing–based assay for minimal residual disease assessment in AML patients with FLT3-ITD mutationsPMID 29643105Read ↗

Minimal residual disease in acute myelogenous leukemia.Semantic proximity Read ↗

Molecular Minimal Residual Disease Monitoring in Acute Myeloid Leukemia: Challenges and Future Directions.Semantic proximity Read ↗

Molecular Minimal Residual Disease Testing in Acute Myeloid Leukemia: A Review for the Practicing Clinician.Semantic proximity Read ↗

<em>FLT3</em>-ITD Measurable Residual Disease in Acute Myeloid Leukemia: Implications for <em>FLT3</em> Inhibitor-Based TherapiesSemantic proximity Read ↗

Sequencing-Based Measurable Residual Disease Testing in Acute Myeloid LeukemiaSemantic proximity Read ↗

Mutation- and MRD-informed treatment decisions for the transplant-eligible AML patient.Semantic proximity Read ↗

Next-generation sequencing for measuring minimal residual disease in AML.Semantic proximity Read ↗

Measurable residual disease monitoring by NGS before allogeneic hematopoietic cell transplantation in AML.Semantic proximity Read ↗

A novel deep targeted sequencing method for minimal residual disease monitoring in acute myeloid leukemia.Semantic proximity Read ↗

Next‐generation sequencing for measurable residual disease detection in acute myeloid leukaemiaSemantic proximity Read ↗

Novel Tools for Diagnosis and Monitoring of AML.Semantic proximity Read ↗

Next-generation sequencing for minimal residual disease monitoring in acute myeloid leukemia patients with FLT3-ITD or NPM1 mutations.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.